These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9475874)

  • 21. Neuropeptide Y (NPY): a coronary vasoconstrictor and potentiator of catecholamine-induced coronary constriction.
    Macho P; Pérez R; Huidobro-Toro JP; Domenech RJ
    Eur J Pharmacol; 1989 Aug; 167(1):67-74. PubMed ID: 2776842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced neuropeptide Y immunoreactivity and vasoconstriction in mesenteric small arteries from spontaneously hypertensive rats.
    Gradin KA; Li JY; Andersson O; Simonsen U
    J Vasc Res; 2003; 40(3):252-65. PubMed ID: 12902638
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Time-dependent effects of ischaemia on neuropeptide Y mechanisms in pig renal vascular control in vivo.
    Malmström RE; Lundberg JM
    Acta Physiol Scand; 1997 Nov; 161(3):327-38. PubMed ID: 9401585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hemodynamic and sympathetic effects of spinal administration of neuropeptide Y in rats.
    Chen XL; Knuepfer MM; Westfall TC
    Am J Physiol; 1990 Dec; 259(6 Pt 2):H1674-80. PubMed ID: 2260694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of neuropeptide Y on norepinephrine-induced constriction in the rabbit facial artery after carotid artery occlusion.
    Roganović J; Petrović N; Djukić L
    Vojnosanit Pregl; 2014 Jun; 71(6):571-5. PubMed ID: 25039112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of EDRF in the cardiopulmonary dysfunction produced by massive sympathetic activation.
    Pilati CF; Maron MB; Bosso FJ
    J Appl Physiol (1985); 1995 May; 78(5):1642-50. PubMed ID: 7649898
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of age and hyperlipidemia on rabbit coronary responses to neuropeptide Y and the interaction with norepinephrine.
    Corr L; Burnstock G; Poole-Wilson P
    Peptides; 1993; 14(2):359-64. PubMed ID: 8483814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Studies on the mechanism of neuropeptide Y induced potentiation of neurogenic vasoconstriction in the isolated rabbit ear artery.
    Duesler JG; Daly RN; Hieble JP
    Am J Hypertens; 1990 Oct; 3(10):796-9. PubMed ID: 2121165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sympathetic vascular control of the pig nasal mucosa (III): Co-release of noradrenaline and neuropeptide Y.
    Lacroix JS; Stjärne P; Anggärd A; Lundberg JM
    Acta Physiol Scand; 1989 Jan; 135(1):17-28. PubMed ID: 2911948
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuropeptide Y is a potent vasoconstrictor and a cardiodepressant in rat.
    Zukowska-Grojec Z; Marks ES; Haass M
    Am J Physiol; 1987 Nov; 253(5 Pt 2):H1234-9. PubMed ID: 3688263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuropeptide Y (NPY) and sympathetic control of blood flow in oral mucosa and dental pulp in the cat.
    Edwall B; Gazelius B; Fazekas A; Theodorsson-Norheim E; Lundberg JM
    Acta Physiol Scand; 1985 Oct; 125(2):253-64. PubMed ID: 2866663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transmural regulation of myocardial perfusion by neuropeptide Y.
    Gutterman DD; Morgan DA
    Basic Res Cardiol; 1995; 90(4):348-55. PubMed ID: 8534260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential action of hepatic sympathetic neuropeptides: metabolic action of galanin, vascular action of NPY.
    Mundinger TO; Taborsky GJ
    Am J Physiol Endocrinol Metab; 2000 Mar; 278(3):E390-7. PubMed ID: 10710492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Neuropeptide Y, orthosympathetic nervous system, hypertension and alpha-2 adrenergic receptors].
    Poncet MF; Tavernier G; Damase-Michel C; Tran MA; Berlan M; Montastruc JL; Montastruc P
    Arch Mal Coeur Vaiss; 1991 Aug; 84(8):1239-41. PubMed ID: 1659347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuropeptide Y restores non-receptor-mediated vasoconstrictive action in superior mesenteric arteries in portal hypertension.
    Hartl J; Dietrich P; Moleda L; Müller-Schilling M; Wiest R
    Liver Int; 2015 Dec; 35(12):2556-63. PubMed ID: 26010514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eicosapentaenoic acid inhibits vasoconstrictor- and noradrenaline-potentiating effects of neuropeptide Y in the isolated rabbit ear.
    Juan H; Sametz W; Saria A; Pöch G
    J Auton Nerv Syst; 1988 Apr; 22(3):237-42. PubMed ID: 2843588
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pulmonary vascular response to endothelin in rats.
    Raffestin B; Adnot S; Eddahibi S; Macquin-Mavier I; Braquet P; Chabrier PE
    J Appl Physiol (1985); 1991 Feb; 70(2):567-74. PubMed ID: 2022547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vasoconstrictor effects in vivo and plasma disappearance rate of neuropeptide Y in man.
    Pernow J; Lundberg JM; Kaijser L
    Life Sci; 1987 Jan; 40(1):47-54. PubMed ID: 3796213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Release of neuropeptide Y upon haemorrhagic hypovolaemia in relation to vasoconstrictor effects in the pig.
    Rudehill A; Olcén M; Sollevi A; Hamberger B; Lundberg JM
    Acta Physiol Scand; 1987 Dec; 131(4):517-23. PubMed ID: 3442241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vasoconstrictor effect of neuropeptide Y (NPY) on canine coronary artery.
    Aizawa Y; Murata M; Hayashi M; Funazaki T; Ito S; Shibata A
    Jpn Circ J; 1985 Jun; 49(6):584-8. PubMed ID: 3839860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.